To enhance adaptive immunity, YIV-906 reduces PD1 or counteracts PD-L1 induction caused by anti-PD1, leading to higher T-cell activation-associated gene expression in the tumor (Yang et al., 2021). The gene discussed is CD274; the disease is neoplasm.